Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Sales (2016 - 2025)

Historic Return on Sales for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 0.03%.

  • Anika Therapeutics' Return on Sales rose 9800.0% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.4% for FY2024, which is 2600.0% up from last year.
  • Latest data reveals that Anika Therapeutics reported Return on Sales of 0.03% as of Q3 2025, which was up 9800.0% from 0.02% recorded in Q2 2025.
  • Anika Therapeutics' Return on Sales' 5-year high stood at 0.17% during Q2 2021, with a 5-year trough of 5.58% in Q4 2023.
  • Over the past 5 years, Anika Therapeutics' median Return on Sales value was 0.08% (recorded in 2022), while the average stood at 0.6%.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -35200bps in 2022, then skyrocketed by 49500bps in 2024.
  • Anika Therapeutics' Return on Sales (Quarter) stood at 0.09% in 2021, then plummeted by -3902bps to 3.61% in 2022, then crashed by -55bps to 5.58% in 2023, then skyrocketed by 89bps to 0.63% in 2024, then soared by 105bps to 0.03% in 2025.
  • Its Return on Sales stands at 0.03% for Q3 2025, versus 0.02% for Q2 2025 and 0.03% for Q1 2025.